Unexplained infertility, or subfertility as it is increasingly being termed, is the diagnosis of exclusion given to couples who have completed a standard infertility evaluation with no abnormal findings. The reported prevalence has ranged from 6 -58%, 1 with large differences in patient populations, referral patterns, evaluation protocols, and interpretations of diagnostic studies. A common standard evaluation, as outlined by the Practice Committee of the American Society of Reproductive Medicine 2 includes a semen analysis, a postcoital test, an assessment of ovulation, a hysterosalpingogram, and, if indicated, a laparoscopy. It is estimated that such an evaluation will fail to identify an abnormality in approximately 15% of couples. 3 Despite the advent of increasingly sophisticated diagnostic modalities in recent years, the standard infertility evaluation has not changed significantly since the widespread use of diagnostic laparoscopy in the 1970s. It has focused primarily on gamete production and transport with little ability to assess gamete interaction, fertilization, embryonic development, or implantation. Therapies to treat unexplained infertility have been developed to deal with theorized abnormalities in these processes with varying degrees of success.
Basic Evaluation
It is imperative that a full evaluation be completed before assigning a diagnosis of unexplained infertility to a couple. A recent chart review in a university reproductive endocrinology clinic noted that more than half of 481 couples presenting for infertility did not have a full standard evaluation for multiple reasons (unpublished observations). A full evaluation may guide specific, successful therapy and avoid interventions with little chance of success.
All standard evaluations include a basic semen analysis to determine the presence of adequate numbers of motile sperm with normal morphology and to document ejaculatory competence. A postcoital test confirms deposition of sperm at the cervical os, appropriate preovulatory cervical mucus, and some evidence of appropriate spermmucus interaction. A hysterosalpingogram will document a normal endometrial cavity and tubal patency but is less predictive of pelvic pathology. In the presence of an abnormal hysterosalpingogram, or a history or symptoms suggestive of pelvic disease, a laparoscopy is mandatory to fully evaluate possible anatomic infertility.
Ovulation must be assessed both for occurrence and adequacy. Basal body temperatures remain an inexpensive qualitative assessment of progesterone secretion and presumed ovulation. A late luteal endome-trial biopsy will reflect cumulative progesterone exposure and assess luteal function but involves discomfort, expense, and subjective interpretation. A serum progesterone level obtained in the midluteal phase as determined by the day of ovulation is a less invasive way to assess luteal function, although controversy persists regarding the lower limit of normal. The development of sensitive, relatively inexpensive home urinary tests to detect the luteinizing hormone surge and pinpoint the day of ovulation has reduced the uncertainty in interpretation of progesterone levels by better-identifying the time of peak progesterone secretion at which to obtain serum.
ADVANCED EVALUATION
Numerous studies have attempted to identify other causes of infertility in couples with a normal standard evaluation. In an intense, controlled study of neuroendocrine function, women with unexplained infertility demonstrated higher, but normal, follicular phase gonadotropin and estradiol levels and lower midluteal progesterone levels than did normal controls, 4 interpreted as suggesting early decreased ovarian reserve. Hofmann et al identified decreased ovarian reserve in 14 of 134 patients with unexplained infertility as screened by the clomiphene citrate challenge test 5 and a markedly decreased in vitro fertilization (IVF) success rate in the presence of decreased reserve. Newer modalities to evaluate ovarian reserve, including early follicular inhibin B-levels, are undergoing evaluation and may provide earlier or more precise identification of this clinical problem. Some evaluation of ovarian reserve should be considered in couples with unexplained infertility.
A number of functional sperm assays, including the zona-free hamster egg penetration assay, the hemizona binding assay, and the acrosome reaction assay, have been developed to evaluate sperm functional capacity, either of binding or penetration of the oocyte. These assays have not yet been proven to adequately predict sperm func-tion and remain controversial as appropriate tests for couples with unexplained infertility. However, 17-20% of couples undergoing IVF for unexplained infertility have demonstrated complete failure of fertilization, 6,7 suggesting a functional problem with gamete interaction. Pending a validated laboratory assessment of sperm-egg interaction, IVF may serve as such an assessment in addition to an aggressive therapy for unexplained infertility.
TREATMENT
Therapies to improve fecundity in couples with unexplained infertility have generally attempted to improve gamete quality, increase gamete numbers, or facilitate gamete interaction. A number of treatments have now been demonstrated to increase the probability of conception in treated cycles to varying degrees. In general, clinical trials are somewhat limited and have significant design differences that make comparisons difficult.
Time
Spontaneous conceptions in couples with unexplained subfertility are well-documented with cumulative pregnancy rates as high as 80% at 5 years of follow-up. A recent Canadian study 8 noted a 23.6% cumulative pregnancy rate at 36 months after a diagnostic laparoscopy to verify the diagnosis. Unfortunately, it is not yet possible to predict which couples will conceive spontaneously or in what time frame, a fact quite frustrating to many. However, it is appropriate to counsel couples with a valid diagnosis of unexplained infertility after a full evaluation that watchful waiting with timed intercourse at home still holds the distinct possibility of pregnancy.
Intrauterine Insemination
Intrauterine insemination (IUI) alone for unexplained infertility or male subfertility has not been well-studied but was recently compared with IUI with mild ovarian stimulation and IVF. 9 The spontaneous monthly 898 RANDOLPH fecundity rate in untreated cycles was 1.25% with a cycle fecundity rate in the IUI alone cycles of 7.4%. This was not statistically different than the 8.7% seen in stimulated IUI cycles or the 12.2% fecundity rate seen in IVF cycles. All IUI samples had at least one million total motile sperm per insemination.
Clomiphene Citrate
The use of clomiphene citrate alone to treat unexplained infertility was recently reviewed 10 with five randomized clinical trials included in the analysis, although four used a crossover design with concerns regarding possible selection bias. One of the trials also included IUI for all patients administered clomiphene, and two other studies used insemination techniques in both treatment arms. The combined odds ratio for treatment compared with controls of pregnancy per patient was a significantly positive 2.37 with a similar odds ratio of 2.50 for conception per cycle. These data suggest a modest increase in fecundity with use of clomiphene citrate in couples with unexplained infertility.
Gonadotropins
A number of trials have evaluated the use of gonadotropins with intercourse or intracervical insemination for the treatment of unexplained infertility. A recent, wellcontrolled, prospective trial conducted by the National Cooperative Reproductive Medicine Network randomized 932 couples to one of four treatment arms, including gonadotropins with intracervical insemination. 11 The couples in the group receiving gonadotropins with intracervical insemination were nearly twice as likely to conceive as the group receiving intracervical insemination alone, with a cumulative pregnancy rate after three cycles of therapy of 19%. A combined analysis of multiple therapies for unexplained infertility 12 estimated a combined per cycle pregnancy rate of 7.7% for gonadotropin therapy alone.
Stimulation With Intrauterine Insemination
At least five trials of clomiphene citrate together with the IUI have been reported with a combined pregnancy rate of 6.7% per initiated cycle. 12 A direct comparison of clomiphene versus clomiphene with IUI has not been reported to date, but the difference, if real, appears to be quite small.
Multiple studies have reported the use of gonadotropins and IUI together with the majority suggesting a substantial increase in cycle fecundity with the addition of IUI to gonadotropin stimulation. The combined analysis of 14 trials 12 netted an 18% per cycle pregnancy rate with combined therapy. In the National Cooperative Reproductive Medicine Network trial, 11 a 33% cumulative pregnancy rate after three cycles of combined therapy was noted. It must be noted, however, that in this trial, semen containing any motile sperm was used for IUI processing and insemination. The trial by Goverde et al 9 using "low-dose" gonadotropins and IUI did not demonstrate any increase in the cycle fecundity rate compared with IUI alone (8.7% vs 7.4%, respectively).
In Vitro Fertilization
At least 10 studies have reported on the use of IVF for unexplained infertility. The rationales for IVF are to increase the number and quality of oocytes available for fertilization, to facilitate the sperm-oocyte interaction and enhance fertilization, to document the occurrence of fertilization, and to evaluate embryo quality. Fertilization failure as an explanation for unexplained infertility has been documented in 17-20% of couples undergoing IVF in recent studies. 6, 7 The quality of the reports of IVF for unexplained infertility varies considerably, with pregnancy rates per cycle ranging from 12.2% 9 to 32.4%. 13 A multicenter, semirandomized, prospective study by the European Society of Human Reproduction and Embryology reported a 25.7% cycle fecundity rate. 14 A meta-analysis by the
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Human Fertilization and Embryology Authority noted a cycle fecundity rate of 17.4% in 2,252 treatment cycles. Guzick 12 reported a corrected cycle fecundity rate of 20.7% in 683 IVF cycles.
Gamete Intrafallopian Transfer and Zygote Intrafallopian Transfer

INTRAFALLOPIAN TRANSFER
Gamete intrafallopian transfer and zygote intrafallopian transfer are variations of IVF that purport to enhance the probability of pregnancy by placing either gametes or zygotes in the distal fallopian tube in an optimal environment for fertilization and development. Both processes require the same stimulation as IVF but are more invasive. Gamete intrafallopian transfer does not allow the determination of fertilization and neither procedure permits assessment of embryonic development.
Cycle fecundity rates for gamete intrafallopian transfer in patients with unexplained infertility range from 19 -28.6%, 12 whereas cycle fecundity rates for zygote intrafallopian transfer have been reported from 32-48.1%. 12 An adjusted cycle fecundity rate of 27% has been reported for gamete intrafallopian transfer. 12 Gamete intrafallopian transfer and zygote intrafallopian transfer are not performed at many assisted reproductive technology centers because they are more invasive and more expensive. Moreover, as IVF cycle fecundity rates have increased, the purported advantage of higher pregnancy rates has not been sustained.
ALTERNATIVE THERAPIES
Multiple other treatment modalities have been proposed or attempted for the treatment of unexplained infertility. The majority have insufficient evidence to adequately access efficacy.
The use of bromocriptine has been stud-ied without clear evidence of improved cycle fecundity. A pooled analysis found insufficient evidence to support the use of bromocriptine for unexplained infertility. 15 Similarly, danazol has been studied in the treatment of unexplained infertility with insufficient evidence to make a conclusion from pooled analysis. 16 Danazol causes significant side effects including acne, hirsutism, and more severe androgen-induced symptoms. Fallopian sperm perfusion, the transcervical installation of a higher-volume sperm preparation than IUI, was also found to have insufficient evidence to support use in pooled analysis. 16 In contrast, cycle fecundity is increased after the use of oil-based contrast media for hysterosalpingogram when compared with water-based media. The overall odds ratio was 1.92 in a pooled analysis. 17
Conclusion
The treatment of unexplained infertility is hampered primarily, by definition, by the lack of a specific abnormality the practitioner can attempt to correct. As our understanding of basic reproductive processes, particularly gamete and embryo biology, improves, it will lead to more specific therapy for specific diagnoses and fewer cases of unexplained infertility.
Rational treatment of unexplained infertility is also hampered by a lack of sufficient, randomized, controlled, prospective clinical trials to satisfactorily practice evidenced-based medicine. Based on the available information, and assuming a thorough investigation for possible causes of infertility, it is reasonable to recommend an escalating course of superovulation with intrauterine insemination and then in vitro fertilization. Clomiphene citrate with IUI offers an improvement in cycle fecundity at a relatively modest cost over a short course of four cycles. Gonadotropins with IUI are more expensive but appear to be substantially more effective at improving cycle fecundity. In vitro fertilization appears to in-crease cycle fecundity somewhat more, but at a substantially increased cost. It does offer the advantage of evaluating fertilization and embryonic development, and is appropriate if less aggressive modalities have not succeeded. However, IVF does not appear to be optimal front-line therapy for couples with unexplained infertility.
